Ca2+-driven self-amplified nanoplatform targeting ER-mitochondrial calcium crosstalk for synergistic apoptosis induction and tumor immune microenvironment remodeling Authors: Yucui Ding, Xinyu Liu, Jianlong Fu, Jianyue Xue, Xueni Fan, Yundong Wang, Xinrui Li, Sirui Liu, Yunchao Yang, Xiaopeng Xu, Gangqiang Yang, Hongbo Wang, Peng Zhang Published: 2026 ABSTRACT AbstractBreast cancer chemotherapy faces severe limitations due to multidrug resistance and metastasis. Herein, we report a rationally designed ORI-LDH@LP (OLL) nanoplatform that establishes a self-reinforcing vicious cycle among endoplasmic reticulum (ER) stress, mitochondrial calcium overload, and oxidative stress to drive irreversible tumor cell apoptosis and reshape the immunosuppressive tumor microenvironment. This nanoplatform comprises oridonin-loaded Mn2+-based layered double hydroxides encapsulated within folate-targeting liposomes. Upon internalization, released oridonin triggers intense ER stress, activating the PERK-eIF2α-ATF4-CHOP axis and upregulating the IP3R-GRP75-VDAC complex at mitochondria-associated ER membranes to facilitate massive Ca2+ flux into mitochondria. This targeted calcium overload induces mitochondrial permeability transition pore opening, membrane potential collapse, ATP depletion, and reactive oxygen species (ROS) burst. Concurrently, released Mn2+ catalyzes hydroxyl radical generation via Fenton-like reactions, synergistically amplifying oxidative damage. This interplay between ER stress-mediated calcium signaling and Mn2+-catalyzed ROS generation creates a self-amplifying cascade that drives mitochondrial-dependent apoptosis. Beyond direct cytotoxicity, the ROS storm triggers immunogenic cell death, while Mn2+ robustly activates the cGAS-STING pathway, establishing a positive feedback loop that amplifies innate immune signaling. This dual mechanism promotes type I interferon production, driving tumor-associated macrophage repolarization from the protumoral M2 to the antitumoral M1 phenotype and enhancing cytotoxic T lymphocyte infiltration. In 4T1 tumor-bearing mice, OLL achieved remarkable tumor suppression without systemic toxicity, demonstrating potent antitumor efficacy through combined direct killing and systemic immune activation. This study establishes a nanomaterial-driven paradigm for precisely modulating ER-mitochondria crosstalk to overcome drug resistance and ignite antitumor immunity, offering a promising strategy for cancer nanotherapeutics.Keywords: Endoplasmic reticulum stress, Mitochondrial calcium overload, Immunogenic cell death, cGAS-STING pathway, Tumor-associated macrophage repolarization Introduction Breast cancer is the most common cancer among women worldwide. According to the 2024 Global Cancer Statistics, it accounts for approximately 32% of all new diagnoses [1]. Although chemotherapy remains a primary modality in clinical treatment, its effectiveness as a monotherapy is significantly limited by acquired multidrug resistance and tumor metastasis [[2], [3], [4]]. To address these limitations, various strategies have been developed to overcome multidrug resistance (MDR) and metastasis in breast cancer. Among them, efficient drug delivery nanoplatforms that synergistically integrate multiple therapeutic modalities with immune activation represent an emerging paradigm [5]. Notably, multidrug-resistant breast cancer cells often develop adaptive endoplasmic reticulum stress responses that promote survival [6]. Targeting the endoplasmic reticulum-mitochondrial calcium axis represents a promising strategy to overcome efflux pump-mediated resistance, as inducing mitochondrial calcium overload can directly trigger lethal damage independent of intracellular drug accumulation [7]. As the largest membrane-bound cellular compartment in cells, the endoplasmic reticulum (ER) plays an important role in several cellular activities, such as protein synthesis, folding and modification, lipid biosynthesis and maintaining calcium homeostasis. ER impairment leads to the accumulation of unfolded or misfolded proteins, further activating the endoplasmic reticulum stress (ERS) [[8], [9], [10], [11]]. ERS upregulates mitochondria-associated ER membrane (MAM) proteins, which facilitates a substantial influx of calcium from the ER to mitochondria [12]. This endogenous Ca2+ influx provokes mitochondrial Ca2+ overload [13,14], subsequently triggering the opening of the mitochondrial permeability transition pore (mPTP) [15,16]. This cascade results in the loss of mitochondrial membrane potential, impaired ATP synthesis, and enhanced reactive oxygen species (ROS) generation, ultimately activating downstream regulated cell death pathways [[17], [18], [19]]. At the same time, mitochondrial ROS and metabolic dysfunction amplify ERS, creating a vicious cycle that exacerbates cellular damage and promotes the release of damage-associated molecular patterns (DAMPs) [20,21]. Therefore, utilizing ER-mitochondrial crosstalk to amplify inter-organellar stress signaling offers a promising strategy to enhance anti-tumor effects. However, this anti-tumor approach is often constrained by the immunosuppressive tumor microenvironment (TME) [22]. During tumor progression, cancer cells undergo metabolic reprogramming to establish a nutrient-deprived, acidic, and hypoxic TME [[23], [24], [25]], which attracts immunosuppressive cells and impairs effector T-cells function [26,27]. Among these infiltrating cell populations, tumor-associated macrophages (TAMs) play a crucial role in maintaining this immunosuppressive state [28,29]. Tumor cells induce the polarization of TAMs toward the immunosuppressive M2 phenotype, thereby promoting tumor progression through the secretion of anti-inflammatory cytokines such as IL-10 [30,31]. Repolarizing TAMs to the pro-inflammatory M1 phenotype is a highly promising strategy in cancer immunotherapy to reverse immunosuppression [[32], [33], [34]]. Oridonin (ORI), a diterpenoid compound isolated from the traditional Chinese herb Rabdosia rubescens, exhibits potent antitumor effects through multiple mechanisms, including cell cycle arrest, apoptosis induction, and migration suppression [[35], [36], [37]]. Recent studies have demonstrated that ORI can also activate ERS-related pathways and promote ROS production [36,38,39]. However, its poor water solubility, low stability, and short half-life severely limit its clinical application [39,40]. Layered double hydroxides (LDHs), a class of two-dimensional nanomaterials [41], hold great potential in drug delivery applications owing to their excellent biocompatibility, tunable chemical composition, and unique ion exchange capability [[42], [43], [44]]. As essential metal ions, manganese ions (Mn2+) participate in multiple physiological processes, particularly in regulating innate immunity [45,46]. Studies have shown that Mn2+ potentiates the cGAS-STING pathway by acting as a direct cGAS activator and increasing the binding affinity of cGAS-STING [[47], [48], [49], [50]]. The incorporation of Mn2+ into LDH endows the Mn-based LDH platform with immunomodulatory capabilities [51,52]. On the one hand, Mn2+ could directly activate the cGAS-STING pathway [53,54]; on the other hand, Mn2+-mediated Fenton-like reactions catalyze the generation of hydroxyl radicals (∙OH) to amplify lethal oxidative stress, thereby triggering immunogenic cell death (ICD), promoting the release of damage-associated molecular patterns (DAMPs) and tumor antigens to alert the immune system [[55], [56], [57], [58]]. This activation precipitates a outburst of type I interferons and pro-inflammatory cytokines, effectively stimulating innate immunity [59,60]. In this study, we constructed a multifunctional nanoplatform to achieve the synergistic cascade of mitochondrial calcium overload, oxidative stress, and immunomodulation. Multidrug-resistant breast cancer cells were employed as the experimental model to evaluate the therapeutic efficacy. Mn2+-based LDH was synthesized via a hydrothermal strategy to load ORI, and ORI-LDH was encapsulated into folate-functionalized liposomes to obtain ORI-LDH@LP (OLL), thereby enhancing stability and tumor-targeting capability. Upon intracellular internalization, OLL dissociated and initiated a cascade amplification of intracellular stress responses. The released ORI induced intense ERS, driving massive Ca2+ translocation to the mitochondria. This targeted calcium flux resulted in mitochondrial calcium overload, thereby triggering mitochondrial dysfunction and ROS burst. Meanwhile, Mn2+ directly catalyzed ∙OH generation via Fenton-like reactions. The interplay between ERS-induced Ca2+ overload and Mn2+-catalyzed ROS generation synergistically exacerbated mitochondrial dysfunction, inducing a lethal ROS burst. This self-amplifying stress cascade triggered mPTP opening, mitochondrial membrane potential collapse, and ATP depletion, initiating mitochondrial-dependent apoptosis. More importantly, the OLL nanoplatform could reshape the tumor immune microenvironment to enhance antitumor immunity. Beyond the ROS storm induced by OLL that could trigger ICD, the incorporated Mn2+ robustly activated the cGAS-STING pathway, thereby establishing a positive feedback loop to amplify innate immune signals. This synergistic integration of ICD and cGAS-STING activation promoted type I interferon production, thereby driving the polarization of TAMs from M2 phenotype to M1 phenotype and enhancing T cell-mediated antitumor immune responses (Scheme 1). To further validate these findings in vivo, the antitumor efficacy of OLL was evaluated in 4T1 tumor-bearing mice. As anticipated, OLL demonstrated remarkable tumor-suppressive capabilities. Aside from directly killing tumor cells and activating local immunity, its antitumor activity was also attributed to the systemic immune activation, establishing long-term immune memory to prevent tumor recurrence and metastasis. Schematic illustration of the anti-tumor mechanism of ORI-LDH@LP nanomedicine. ORI-LDH@LP (OLL) is internalized by tumor cells via folate receptor-mediated endocytosis. Upon internalization, ORI induces endoplasmic reticulum stress (ERS) by activating the PERK-eIF2α-ATF4-CHOP pathway, while Mn2+ catalyzes the generation of hydroxyl radicals (·OH) through Fenton-like reaction. ERS further upregulates the IP3R-GRP75-VDAC complex at ER-mitochondria contact sites, leading to massive Ca2+ transfer into mitochondria. Mitochondrial Ca2+ overload triggers mPTP opening and a burst of ROS. The interplay among endoplasmic reticulum stress, Ca2+ overload, and ROS storm establishes a self-amplifying vicious cycle. This cascade promotes mitochondria-dependent apoptosis and immunogenic cell death. Meanwhile, Mn2+ activates the cGAS-STING pathway, promoting the production of type I interferons. These events remodel the tumor immune microenvironment by repolarizing tumor-associated macrophages (TAMs) from M2 to M1 phenotype and enhancing CD4+/CD8+ T cell infiltration, ultimately leading to potent antitumor immunity and tumor cell death. Results Characterization of LDHs and ORI-LDH@LP Mn-based LDH was synthesized via the hydrothermal method with different M2+/M3+ ratio. Among the tested formulations, the Mn/Al molar ratio of 2:1 yielded nanoparticles with the most favorable size distribution. DLS measurements showed that the hydrodynamic diameter of the prepared LDH was approximately 185 nm. ORI-LDH was subsequently fabricated through an anion exchange reaction, the particle size was increased to about 220 nm (Fig. 1A and B), indicating the successful incorporation. The elemental composition and morphology of LDH were further characterized. ICP analysis revealed that the manganese and aluminum contents were 10% and 35%, respectively (Fig. 1C). TEM images confirmed the typical hexagonal layered morphology of LDH (Fig. 1D) [61] and the particle size of LDH determined by TEM was consistent with DLS measurements. TEM elemental mapping of O, Al and Mn was carried out to further confirm that Mn2+ ions were successfully incorporated into the LDH (Fig. 1E). ORI-LDH was subsequently encapsulated into liposomes using the ethanol injection method to obtain ORI-LDH@LP (denoted as OLL). The hydrodynamic diameter of OLL increased to around 300 nm, reflecting the formation of a lipid coating around the LDH core (Fig. 1F), and TEM imaging clearly showed LDH structures were successfully incorporated into liposomal vesicles (Fig. 1G). In contrast to the increase in particle size, the zeta potential of OLL shifted from +23.70 mV (ORI-LDH) to −9.25 mV (Fig. 1H), consistent with successful liposomal encapsulation and surface charge reversal. FTIR spectroscopy verified the successful loading of ORI. As shown in Supporting Fig. S1, the ORI-LDH spectrum exhibited the characteristic stretching vibrations of ORI superimposed on the LDH spectrum. Importantly, the spectrum of ORI-LDH differed distinctly from that of a simple physical mixture (Fig. S2), confirming successful drug intercalation rather than surface adsorption. Furthermore, the appearance of lipid-associated peaks in the OLL spectrum indicated the formation of liposome-coated nanostructures. The encapsulation efficiencies of ORI in ORI-LDH (at an optimized ORI:LDH ratio of 1:2, w/w) and OLL were 80% and 70%, respectively (Fig. S3). The stability of OLL was evaluated under different pH conditions, Fig. 1I revealed excellent stability, with no obvious nanoparticle size change over one week. ORI release profiles highlighted the pH-responsive release behavior of OLL, with cumulative ORI release reaching approximately 80% at pH 6.5 compared to only 50% at pH 7.4 (Fig. 1J) within 72 h. In addition, the release profiles of Mn2+ and Al3+ from OLL were also evaluated under acidic (pH 6.5) and physiological (pH 7.4) conditions. As shown in Fig. 1K, and Fig. S4, both ions exhibited accelerated release at pH 6.5, consistent with the degradation behavior of LDH. The catalytic activity of LDH was evaluated via EPR spectroscopy, confirming ·OH generation (Fig. 1L). This was further confirmed by a cell-free ·OH detection assay (Fig. S5), demonstrating that Mn2+ incorporated in the LDH lattice promoted ·OH generation via Fenton-like process. Characterization of LDH and OLL. (A) and (B) Particle size of LDH and ORI-LDH measured by dynamic light scattering (DLS). (C) The content of Mn and Al in LDH (n = 3). (D) TEM images of OLL (Scale bar = 50 nm). (E) Elemental mapping of LDH. Elemental mapping images where O, Al, and Mn are in green, yellow and red colors, respectively (Scale bar: 20 nm). (F) The particle size of OLL measured by dynamic light scattering. (G) TEM images of OLL. Scale bar = 100 nm. (H) Zeta potential of LDH, ORI-LDH and OLL (n = 3). (I) Variation in the particle size of the preparation in different media (n = 3). (J) Release profiles of ORI from OLL in media at different pH value (n = 3). (K) Release curve of Mn2+ from OLL in phosphate buffers of different pH (n = 3). (L) EPR Image determine •OH production from the LDH. Superiority of OLL-based treatment against tumor cells in vitro Following the successful preparation of OLL, in vitro experiments were conducted to validate the antitumor efficacy of OLL. Biosafety was first evaluated via a hemolysis assay. OLL exhibited excellent biocompatibility, with a hemolysis rate of merely 3% even at high concentration of 200 μg/mL (Fig. 2A), indicating the biocompatibility of Mn-based LDH in tumor therapy [62]. To further evaluate the safety of the formulations, we assessed the cytotoxicity of each formulation on normal cell lines, including L929 fibroblasts and RAW 264.7 macrophages. As shown in Figs. S6 and S7, OLL did not significantly reduce the viability of these normal cells even at ORI concentrations as high as 10 μg/mL (all >80% viability). Cellular uptake was then examined in MCF-7/ADR cells using Coumarin-6-labeled OLL. Fluorescence microscopy showed clear time-dependent internalization of OLL, with green signals appearing after 2 h and peaking at 8 h, indicating efficient tumor cell entry (Fig. 2B and S8). This rapid and sustained accumulation suggested that the liposomal outer shell facilitated effective membrane interaction and endocytosis [63]. To quantitatively evaluate the synergistic effect between ORI and LDH, we used the Chou-Talalay method to calculate the combination index (CI). At different concentration ratios (ORI: 4–10 μg/mL; LDH: 8–20 μg/mL), the CI values were all below 0.6, and at an ORI concentration of 4 μg/mL (LDH 8 μg/mL), the CI value was 0.51, indicating a strong synergistic effect (Fig. S9). Subsequently, the antitumor effects of OLL were evaluated against multidrug-resistant MCF-7/ADR cells. After 24 h, blank liposomes showed negligible cytotoxicity against MCF-7/ADR cells, while LDH and ORI treatment exhibited mild to moderate inhibition. In contrast, OLL significantly inhibited cell proliferation and markedly reduced cell viability in a concentration-dependent manner (Fig. 2C). The enhanced cytotoxicity of OLL compared to free ORI + free Mn2+ suggested improved intracellular drug delivery and potential synergistic effects between ORI and Mn-based LDH (Fig. S10). Superiority of OLL against tumor cells in vitro. (A) Hemolysis experiment of erythrocytes incubated with OLL at various concentrations. (B) Fluorescence microscope images of MCF-7/ADR cells treated by OLL (scale bar: 50 μm). (C) Viability of MCF-7/ADR cells incubated with different concentrations of NPs (24 h). (D) Live/dead staining of the cells treated with different scenarios (24 h) (Scale bar 50 μm). (E) Wound healing assay shows the migration of MCF-7 cells after 24 h and 48 h co-culture with various concentrations of different agents (Scale bar 100 μm). Data represent mean ± SD (n = 3). Statistical significance was determined by one-way ANOVA with Tukey's post-hoc test (for multi-group comparisons). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. Based on the inhibition profiles, an ORI concentration of 4 μg/mL was selected as the optimal concentration for subsequent experiments. Furthermore, this potent inhibitory effect was also observed in HepG2 and 4T1 cell lines (Figs. S11–S13), confirming the broad-spectrum antitumor activity of OLL. To investigate the underlying mechanisms, 4-PBA (ERS inhibitor) or BAPTA-AM (calcium chelator) was added to the OLL treated groups. The viability of MCF-7/ADR cells was significantly rescued (Figs. S14 and S15), suggesting that ERS and calcium overload may be pivotal mechanisms for the anti-tumor activity of OLL. The antitumor effect of OLL was further visually confirmed via Calcein-AM/PI double staining. Consistent with the viability assays results, the OLL-treated group displayed a marked shift from green (live cells) to red (dead cells) fluorescence after 24 h, with the red fluorescence intensity of dead cells exceeding 60% (Fig. 2D and S16). Conversely, the addition of 4-PBA or BAPTA-AM significantly preserved the green fluorescence signal, and the live-cell green fluorescence intensity in these two groups was higher than that in the ORI-only group. These results indicated that ERS and calcium overload were indispensable for OLL-mediated cytotoxicity. After 48 h, the trend was consistent with that at 24 h, and the green fluorescence signal in the OLL group was nearly undetectable, reflecting enhanced tumor cell cytotoxicity (Fig. S17). In addition to direct tumor cell killing effects, OLL also significantly impaired tumor cell migration, as demonstrated by wound healing assays (Fig. 2E and S18). After 24 and 48 h, OLL treatment markedly inhibited the migration of MCF-7/ADR cells compared to other groups. Importantly, this migration inhibitory effect was reversed by both 4-PBA and BAPTA-AM, further linking OLL-induced ERS and calcium dysregulation to the suppression of tumor cell motility. OLL mediates ROS generation and mitochondrial damage through the induction of endoplasmic reticulum stress Given the excellent antitumor activity of OLL, the underlying antitumor mechanisms were further investigated. Considering that the endoplasmic reticulum is highly sensitive to external stimuli, morphological changes were first examined using the ER-Tracker Red probe. As illustrated in Fig. 3A and S19, MCF-7/ADR cells treated with OLL for 12 h exhibited obvious ER morphological swelling (intensified fluorescence compared to control groups), directly confirming the disruption of ER homeostasis and the initiation of ERS. In addition to morphological alterations, ERS is known to induce specific changes in signature proteins expression. The molecular mechanisms of OLL were subsequently investigated via Western blot analysis. As the PERK-eIF2α-ATF4-CHOP axis represents a classical ERS pathway, the expression levels of key proteins within this cascade was analyzed. The data clearly showed robust phosphorylation of PERK (p-PERK) and its downstream substrate eIF2α (p-eIF2α) in the OLL-treated group. This phosphorylation cascade subsequently upregulated the expression of the activating transcription factor 4 (ATF4) and pro-apoptotic protein CHOP (Fig. 3B and Semi-quantitative analysis in Fig. S20), indicating activation of the PERK-mediated ERS cascade. Immunofluorescence staining further validated the activation of this axis. As shown in Fig. 3C and S21, OLL treatment enhanced fluorescence signals of p-PERK, p-eIF2α, ATF4, and CHOP compared to other groups. Notably, CHOP exhibited distinct nuclear translocation, which is a critical step for its pro-apoptotic transcriptional function. Considering CHOP's pivotal role in triggering apoptosis, this nuclear accumulation of CHOP indicated that OLL successfully activated the PERK-eIF2α-ATF4-CHOP axis. Following the activation of ERS, its downstream consequences - cellular redox balance and mitochondrial function - were then investigated. ERS has been reported to trigger ROS generation. As anticipated, DCFH-DA staining revealed a ROS burst in OLL-treated cells, with fluorescence intensity reaching approximately 2-fold that in the control group (Fig. 3D and S22). This severe oxidative stress rapidly overwhelmed the cellular antioxidant defense system [64]. To further determine whether LDH promoted intracellular ·OH generation, HPF staining was performed. As shown in Fig. 3E and S23 LDH and OLL treatments resulted in significantly enhanced HPF fluorescence compared with the control and ORI groups, indicating increased intracellular ·OH generation [65]. Specifically, a significant depletion of intracellular GSH was observed (Fig. 3F). Interestingly, the activity of glutathione peroxidase (GSH-Px) was elevated (Fig. S24), suggesting a compensatory upregulation in response to oxidative stress. However, the protective capacity of GSH-Px was severely limited by substrate (GSH) exhaustion, it's failed to effectively neutralize the intracellular ROS, thereby exacerbating redox imbalance and driving the progression of apoptosis. Under oxidative stress, as the primary cellular targets of ROS, mitochondria undergo immediate functional dysfunction. As shown in Fig. 3G and S25, JC-1 staining results demonstrated a significant decrease of the mitochondrial membrane potential (ΔΨm) in OLL-treated cells. The collapse of mitochondrial membrane potential inevitably led to a sharp decline in intracellular ATP levels (Fig. 3H), resulting in an energy crisis within the cell. Prolonged energy depletion resulted in cellular dysfunction and death. Crucially, the activation of the PERK–eIF2α–ATF4–CHOP pathway not only induced ROS generation but also established a lethal positive feedback loop in which oxidative stress subsequently exacerbated ERS. This mechanism progressively disrupted cellular energy metabolism and redox homeostasis, thereby driving tumor cells toward apoptosis. OLL mediates ROS generation and mitochondrial damage through the induction of ERS. (A) Confocal fluorescence images showing ER staining in MCF-7/ADR cells after different treatments (Scale bars: 50 μm). (B) Western blot assay showing the expression of the p-PERK, p-eIF2α, ATF4 and CHOP in MCF-7/ADR cells treated with the respective formulations for 12 h. (C) Representative fluorescence images for p-PERK, p-eIF2α, ATF4 and CHOP in MCF-7/ADR cells treated with the respective formulations for 12 h (Scale bars: 50 μm). (D)The representative fluorescence images of ROS in MCF-7/ADR cells (Scale bars: 50 μm). (E) ·OH generation detected by HPF (scale bar 20 μm). (F) Intracellular glutathione content in MCF-7/ADR cells treated with the respective formulations for 12 h (a: Control, b: LDH, c: ORI, d: OLL, e: OLL + 4-PBA, f: OLL + BAPTA). (G) The representative fluorescence images of Mitochondrial membrane potential changes in MCF-7/ADR cells (Scale bars: 50 μm). (H) Intracellular ATP Level in MCF-7/ADR cells treated with the respective formulations for 12 h (a: Control, b: LDH, c: ORI, d: OLL, e: OLL+4-PBA, f: OLL + BAPTA). Data represent mean ± SD (n = 3). Statistical significance was determined by one-way ANOVA with Tukey's post-hoc test (for multi-group comparisons). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. Role of ER Stress-Mediated Calcium Dyshomeostasis in Mitochondrial Apoptosis The previous results showed that OLL triggered mitochondrial dysfunction and apoptosis through ERS. We therefore investigated the molecular mechanism between ERS and mitochondrial damage. Given that the ER is the primary intracellular calcium reservoir, and communicates with mitochondria primarily through calcium flux at membrane contact sites, we hypothesized that calcium dysregulation mediates this ER to mitochondria signaling process. Thus, we first examined whether OLL disturbed the intracellular calcium homeostasis. Using the calcium fluorescent probe Fluo-4 AM, Ca2+ levels in MCF-7/ADR cells after 12-h treatment were detected. As illustrated in Fig. 4A and B, a dramatic cytoplasmic Ca2+ fluorescence intensity was observed in OLL-treated MCF-7/ADR cells compared with all other groups, demonstrating that OLL induced a state of severe intracellular calcium overload. The results of Alizarin Red staining were consistent with the above findings (Fig. S26). To clarify whether this overload originates from endoplasmic reticulum leakage and directly affects mitochondria, we examined the IP3R-GRP75-VDAC protein complex located at ER-mitochondrial contact sites (MAMs), which was responsible for direct Ca2+ translocation. OLL treatment increased the protein levels of IP3R, GRP75, and VDAC, as shown by densitometric analysis of multiple Western blots, suggesting upregulation of the ER-mitochondria calcium transfer complex (Fig. 4C and S27). The upregulated expression of Ca2+ channel-related proteins suggested that OLL promoted concentrated Ca2+ influx into mitochondria. Pharmacological inhibition experiments provided additional validation for this process. Pretreatment with the ERS inhibitor 4-PBA significantly suppressed the upregulation of the IP3R-GRP75-VDAC complex, indicating that this calcium channel was regulated downstream of ERS. Interestingly, the calcium chelator BAPTA-AM also reduced the expression levels of these three proteins, indicating that the initial calcium release triggered by OLL further amplified calcium transfer pathways, while BAPTA-AM interrupts this amplification by blocking the initiating calcium signal. A direct consequence of mitochondrial calcium overload is the sustained opening of the mPTP. Thus, the opening state of mPTP was assessed as the indicator of calcium overload induced mitochondrial injury. After 12 h of OLL treatment, MCF-7/ADR cells exhibited significantly reduced fluorescence intensity, indicating irreversible pore opening comparable to the ionomycin positive control (Fig. 4D and E). Both 4-PBA and BAPTA-AM pretreatments notably attenuated mPTP opening, further demonstrating that ERS-driven calcium influx is the primary cause of mPTP activation and subsequent mitochondrial damage. Role of ER Stress-Mediated Calcium Dyshomeostasis in Mitochondrial Apoptosis. (A) The representative fluorescence images of Ca2+ concentration in MCF-7/ADR cells treated with the respective formulations for 12 h (Scale bars: 50 μm). (B) The fluorescence intensity quantitative histogram of A. (C) Western blot assay showing the expression of the IP3R, GRP75 and VDAC in MCF-7/ADR cells treated with the respective formulations for 12 h. (D) The representative fluorescence images for mPTP change in MCF-7/ADR cells treated with the respective formulations for 12 h (Scale bars: 50 μm). (E) The fluorescence intensity quantitative histogram for D. Data represent mean ± SD (n = 3). Statistical significance was determined by one-way ANOVA with Tukey's post-hoc test (for multi-group comparisons). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. These results indicated that OLL induced ERS, which in turn triggered substantial ROS production and cytosolic release. Concurrently, ERS-induced mitochondrial calcium overload disrupted the mitochondrial respiratory chain. This disruption led to robust ROS generation, followed by further release into the cytosol through the prolonged opening of the mPTP. Synergistically, these two pathways established a state of severe oxidative stress. As extensively documented, excessive ROS further aggravated ERS [66] and exacerbated mitochondrial calcium overload [67]. This interplay created a self-reinforcing vicious cycle driven by positive feedback among ERS, calcium signaling, and ROS. Once initiated, this cycle programmed the cell into an irreversible cascade of cell death. It progressively intensified oxidative stress and ultimately caused mitochondrial damage. In synergy with continuous mPTP opening, this process induced the depolarization of the mitochondrial membrane potential, completely suppressed ATP synthesis, and promoted massive cytochrome c release to drive the cell toward apoptosis. Furthermore, treatment with 4-PBA and BAPTA-AM rescued the cells by inhibiting ERS and modulating calcium flux, respectively. These pharmacological interventions provided clear evidence that this positive feedback loop is the primary driver of cellular apoptosis. OLL-Induced Immunogenic Cell Death and Innate Immune Activation The aforementioned experimental results demonstrated that OLL disrupted redox balance and energy production through ERS and calcium overload. Next, the mechanism by which OLL induced program of apoptosis program was investigated. The mitochondrial apoptotic pathway is primarily regulated by the Bcl-2 protein family, which is the molecular rheostat to determine cellular fate. Western blot analysis revealed that OLL treatment significantly upregulated the pro-apoptotic protein BAX while decreasing the anti-apoptotic protein Bcl-2, thereby elevating the BAX/Bcl-2 ratio (illustrated in Fig. 5A and S28). ERS suppressed Bcl-2 protein expression through upregulated CHOP protein, while intracellular calcium overload and ROS burst directly promoted BAX activation and mitochondrial translocation [[68], [69], [70], [71]]. The activated BAX translocated to mitochondria to form pores, increasing mitochondrial outer membrane permeability. This structural change facilitated cytochrome c release into the cytosol, promoting apoptosome formation and Caspase-9 activation. As shown in Fig. 5B, enzymatic assays confirmed Caspase-9 enzyme activity was significantly increased, indicating that Caspase-9 was successfully activated. Activated caspase-9 then cleaved and activated the Caspase-3 (Fig. 5C), inducing irreversible mitochondria-dependent apoptosis. Pretreatment with either 4-PBA or BAPTA-AM substantially reversed these changes, restoring Bcl-2 levels, suppressing BAX activation, and reducing caspase-9 and caspase-3 cleavage. All these results indicate that OLL drives a positive-feedback loop between ERS and calcium signaling that amplifies mitochondrial apoptotic signals. OLL-Induced Immunogenic Cell Death and Innate Immune Activation. (A) Western blot assay showing the expression of the BAX and Bcl-2 in MCF-7/ADR cells treated with the respective formulations for 12 h. (B) The activity of apoptosis-related proteases (Caspase-9) in MCF-7/ADR cells treated with the respective formulations for 12 h. (C) The activity of apoptosis-related proteases (Caspase-3) in MCF-7/ADR cells treated with the respective formulations for 12 h. (D) The representative fluorescence images of CRT in MCF-7/ADR cells treated with the respective formulations for 12 h (Scale bars: 50 μm). (E) HMGB1 concentration in culture supernatants from MCF-7/ADR cells treated with different formulations for 12 h, as determined by ELISA. (F) Western blot assay showing the expression of the cGAS, p-STING, STING, p-TBK1, TBK1, IRF-3, p-P65 and P65 in MCF-7/ADR cells treated with the respective formulations for 12 h. Data represent mean ± SD (n = 3). Statistical significance was determined by one-way ANOVA with Tukey's post-hoc test (for multi-group comparisons). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. The immunologically silent nature of tumor cell apoptosis may limit the therapeutic impact of OLL-induced mitochondria-dependent apoptosis. Notably, ERS and calcium overload have been demonstrated to trigger immunogenic cell death (ICD). We therefore evaluated whether OLL induces ICD to overcome this limitation and amplify anti-tumor efficacy by provoking a specific immune response against the tumor. Classical ICD markers, calreticulin (CRT) and high mobility group box 1 (HMGB1), were examined using immunofluorescence staining. It's observed that OLL-treated cells exhibited significant translocation of CRT to the cell surface membrane along with the nucleocytoplasmic release of HMGB1 (Fig. 5D and E). These damage-associated molecular patterns (DAMPs) function as critical “eat-me” signals, which recruit antigen-presenting cells to initiate anti-tumor immune responses. 4-PBA and BAPTA-AM pretreatments effectively suppressed these immunogenic markers, confirming that OLL-induced ICD is strictly dependent on upstream ERS and calcium signaling. To further counteract the immunosuppressive nature of the tumor microenvironment, we strategically integrated Mn2+ into the LDH for directly activating the cGAS-STING pathway. We first examined whether Mn-Al LDH and Mn-free Mg-Al LDH had different effects on cell viability. Mg-Al LDH was used as a Mn-free LDH control to distinguish the contribution of Mn2+ from that of the LDH nanocarrier itself. Mn-Al LDH alone showed moderate cytotoxicity, whereas Mg-Al LDH exhibited minimal cytotoxicity under the same conditions. Moreover, when combined with ORI, ORI-loaded Mn-Al LDH induced a much stronger decrease in cell viability than ORI-loaded Mg-Al LDH, indicating that Mn2+ plays an important role in the enhanced cytotoxic effect of OLL (Fig. S30). Further western blot analysis (Fig. 5F and S31) demonstrated that OLL treatment significantly upregulated the phosphorylated STING (p-STING), phosphorylated TBK1 (p-TBK1), and phosphorylated P65 (p-P65). These findings suggest that Mn2+ released from the LDH may enhance cGAS enzymatic activity and directly facilitate STING activation, thereby amplifying the innate immune sensing of cyclic dinucleotides. This activation promotes the robust production of Type I interferons and pro-inflammatory cytokines [72]. Pretreatment with either 4-PBA or BAPTA-AM partially suppressed the phosphorylation of these pathway proteins. We speculate that ERS and calcium overload potentiate STING signaling through dual mechanisms. On one hand, 4-PBA inhibits the UPR-mediated transcription of immune components [73,74], whereas BAPTA-AM impedes calcium-dependent signaling amplification, reducing STING activity [75]. On the other hand, by disrupting the ROS-driven apoptotic cycle, both inhibitors preserve mitochondrial integrity and reduce the leakage of mtDNA into the cytosol, thereby limiting the GAS activation [76]. In Vivo Therapeutical Efficacy of OLL and Mechanism Analysis To evaluate the in vivo targeting capability and biodistribution of the nanoplatform, we established a 4T1 tumor-bearing mouse model and administered the formulation labeled with the near-infrared probe DIR (denoted as OLL@DIR) (illustrated in Fig. 6A). As shown in Fig. 6B, fluorescence imaging revealed a time-dependent accumulation of the OLL@DIR at the tumor site, with maximum fluorescence intensity reached at 24 h post-injection, which demonstrating excellent tumor retention properties. Quantitative ROI analysis of the fluorescence images revealed a time-dependent increase in the tumor-to-normal tissue ratio (T/N ratio), from 2.0 ± 0.2 at 2 h to 3.2 ± 0.2 at 12 h and 5.3 ± 0.1 at 24 h (Fig. S32), confirming the progressive accumulation of OLL in the tumor. Ex vivo imaging of major organs at 24 h confirmed obviously higher fluorescence intensity in tumor tissue than in other major organs, indicating strong tumor-targeting capability of the OLL nanoplatform (Fig. 6C). Therapeutic efficacy was then assessed in 4T1 tumor-bearing mice, and tumor volume of each mouse was monitored every two days. From day 7, the OLL-treated group displayed significantly smaller tumor volumes than the control group and monotherapy groups. After 14 days treatment, tumors from OLL-treated mice were the smallest in both volume and weight (Fig. 6D–F). These findings indicated that OLL achieved superior inhibition of tumor growth in vivo compared with monotherapies. In Vivo Therapeutical Efficacy of OLL and Mechanism Analysis. (A) Schematic illustration of the therapeutic procedure; Inoculate 4T1 cells subcutaneously on the left side of mice to simulate a primary tumor. Seven days later, inject the respective formulations into the mouse tail every other day. Then the growth status of mice was observed every 2 days, and mice were dissected and analyzed at 14 days post injection. (B) In vivo biodistribution images of DIR-labeled OLL at 2, 12, and 24 h (n = 3). (C) Fluorescence distribution images of tumor and different organs at 12 h after injection. (D) Relative tumor volume changes during treatment (n = 5). (E) Tumor weight after 14 days of treatment with respective formulations (n = 5). (F) Images of the tumor after 14 days of treatment. (G) H&E, Ki-67 and TUNEL staining of tumor sections collected from mice with different treatments. Scale bar (H&E): 50 μm, scale bar (Ki-67 and TUNEL): 20 μm. (H) The representative fluorescence images of ROS in tumor tissues treated with the respective formulations for 14 d (Scale bar: 50 μm). Data represent mean ± SD. Statistical significance was determined by one-way ANOVA with Tukey's post-hoc test (for multi-group comparisons). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. Histological and immunohistochemical analyses were performed on tumor sections to evaluate proliferation and apoptosis (Fig. 6G). Immunohistochemical analysis revealed a reduction in Ki67-positive cells within OLL-treated tumors, indicating the effective suppression of malignant proliferation. TUNEL staining demonstrated the highest density of apoptotic cells in OLL-treated tumors, characterized by extensive positive regions. H&E staining further confirmed massive cell death by revealing widespread necrotic areas, nuclear pyknosis, and karyorrhexis in the OLL group. To determine whether the in vivo antitumor activity was consistent with the previously defined mechanism, intratumoral ROS levels were detected. The OLL-treated tumor sections exhibited the strongest ROS fluorescence signals (Fig. 6H), indicating severe oxidative stress within the tumor tissue. This observation was in agreement with in vitro results and supported our hypothesis that ERS induced oxidative disruption and apoptosis represent the primary mechanism underlying OLL-mediated tumor suppression in living systems. OLL induces effective anti-tumor immunotherapy Given the demonstrated ability of OLL to activate innate immunity in vitro and its superior antitumor efficacy in vivo, its immunomodulatory effects in tumor-bearing mice were further evaluated. Based on earlier findings, we hypothesized that OLL-induced ICD could initiate adaptive immune responses in vivo. To validate this hypothesis, we first examined tumor sections using immunofluorescence staining. Compared with the control groups, the OLL-treated tumors exhibited significantly enhanced CRT exposure on the cell membrane alongside pronounced HMGB1 nucleocytoplasmic translocation (Fig. 7A and S33). These findings confirmed that OLL effectively induces ICD in tumor cells, thereby releasing DAMPs for subsequent immune activation. Next, the modulation of the immunosuppressive TME by OLL was investigated, specifically targeting tumor-associated macrophages (TAMs). Repolarizing M2-phenotype TAMs, which facilitate tumor immune escape, toward the immunostimulatory M1 phenotype has emerged as a promising therapeutic strategy in cancer immunotherapy. Here, immunofluorescence analysis demonstrated the remarkable capacity of OLL to effectively regulate macrophage polarization. As illustrated in Fig. 7B and S34, OLL treatment significantly downregulated the expression of the M2 marker CD206 while upregulating the M1 marker CD86 within tumor tissues. This indicated that OLL successfully reprogrammed TAMs from pro-tumoral M2 macrophages into antitumor M1 phenotype, which is capable of antigen presentation and direct cytotoxicity, thereby effectively remodeling the immunosuppressive tumor microenvironment. OLL induces effective anti-tumor immunotherapy. (A) The representative fluorescence images of CRT and HMGB1 in tumor tissues treated with the respective formulations for 14 d (Scale bars: 50 μm). (B) The representative fluorescence images of expression level of CD206 and CD86 cells in tumor tissues. (Scale bars: 50 μm). (C) The representative fluorescence images of the level of CD4+ and CD8+ cells in tumor tissues (Scale bars: 50 μm). (D) TNF-α, IL-6, IFN-γ and IFN-β in mice serum from mice 14 d post-injection. Data represent mean ± SD (n = 3). Statistical significance was determined by one-way ANOVA with Tukey's post-hoc test (for multi-group comparisons). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. To determine the functional consequences of ICD induction and TAM reprogramming, we evaluated T cell infiltration within the tumor tissues. As shown in Fig. 7C and S35, the OLL-treated mice displayed a significant increase in the infiltration of both CD4+ T cells and CD8+ T cells. CD4+ T cells are essential for facilitating the maturation of cytotoxic lymphocytes, while CD8+ T cells serve as the primary effectors responsible for tumor clearance. Furthermore, analysis of key inflammatory cytokines revealed that OLL treatment elevated the intratumoral levels of TNF-α, IL-6, IFN-γ, and IFN-β (Fig. 7D). Among these, IFN-γ is a core effector molecule that directly inhibits tumor proliferation and reinforces M1 macrophage polarization. Type I interferons can amplify the activation of DCs and T cells. These cytokines establish a pro-inflammatory microenvironment that sustains a positive feedback loop for the immune response against tumors. We subsequently investigated whether the local immune remodeling induced by OLL could elicit systemic antitumor immunity. Immunofluorescence analysis and flow cytometry of splenic tissue (Fig. 8A and B and S36) showed that OLL treatment induced systemic immune activation that mirrored the changes observed in the tumor. Specifically, splenic macrophages exhibited significant polarization toward the M1 phenotype characterized by downregulated CD206 (M2 marker) and upregulated CD86 (M1 marker) expression. This suggested that the macrophage reprogramming effect of OLL extended beyond the TME to systemically reverse immunosuppression. More importantly, flow cytometric analysis revealed a significant increase in the percentage of CD8+ T cells within the CD3+ T-cell population (Fig. 8C), as well as elevated absolute numbers of both CD4+ and CD8+ T cells in the spleen (Fig. S37). Consistently, immunofluorescence staining showed markedly enhanced CD4+ and CD8+ T-cell signals in the spleen (Fig. 8D and Fig. S38), indicating robust systemic T-cell expansion. This result suggested that tumor antigens released through ICD were successfully transported to secondary lymphoid organs by antigen-presenting cells, where they initiated the clonal expansion of tumor-specific T cells. These expanded T cells can subsequently recirculate via the bloodstream to infiltrate tumor tissue and execute cytotoxic functions to establish a robust systemic antitumor immune response. OLL activates systemic immune response. (A) Representative Fluorescence-activated cell sorting (FACS) plots (left panel) and quantitative analysis (right panel) of CD206 and CD86 tumor-associated macrophages in spleen and lymphatic tissue. (B) The representative fluorescence images of the expression level of CD206 and CD86 cells in Spleen (Scale bars: 50 μm). (C) Representative FACS plots (left panel) and quantitative analysis (right panel) of the percentage of CD8+ T cells within the CD3+ T-cell population in the spleen. (D) The representative fluorescence images of the level of CD4+ and CD8+ cells in tumor tissues (Scale bars: 50 μm). Data represent mean ± SD (n = 3). Statistical significance was determined by one-way ANOVA with Tukey's post-hoc test (for multi-group comparisons). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. In vivo safety of OLL The biosafety of the OLL nanoplatform was also monitored during the treatment period. Body weights remained stable across all groups throughout the study, indicating good general tolerance of OLL (Fig. S39). Hematological analysis showed no abnormal hematological changes, and hematological parameters were within the normal physiological ranges across all groups (Fig. S40). Furthermore, serum biochemical indices (including ALT, AST, BUN, and CREA) further confirmed normal hepatic and renal function, demonstrating no significant systemic adverse effects (Fig. S41). To validate organ-specific safety, histopathological examination was performed via H&E staining on major organs including the heart, liver, spleen, lung, and kidney. As illustrated in Fig. S42, no evident pathological lesions or structural abnormalities were observed. All these findings demonstrate that the OLL exhibited acceptable biocompatibility under the tested dose in this study, with no obvious cytotoxicity or major organ damage observed. Discussion To achieve effective cancer therapy, it is important to simultaneously induce direct tumor cell killing, trigger ICD, and remodel the immunosuppressive TME. Conventional chemotherapy can eliminate tumor cells, but it often fails to elicit durable antitumor immunity and may even contribute to immunosuppression [77]. Chemodynamic therapy (CDT), which generates cytotoxic ·OH through Fenton or Fenton-like reactions, has emerged as a promising strategy for oxidative stress-mediated tumor therapy [78]. However, CDT alone usually provides limited immune activation, and its efficacy can be restricted by insufficient catalytic ion availability and the heterogeneous TME. Nanoparticle-based delivery systems offer an attractive strategy by enabling the co-delivery of catalytic ions, therapeutic agents, and immune modulators to tumor tissues [79,80]. Nevertheless, many existing nanocarriers still rely on relatively single therapeutic mechanisms and lack the ability to coordinate calcium dysregulation, oxidative stress, and immune activation into a self-reinforcing therapeutic cascade. In this study, we developed a multifunctional nanoplatform, ORI-LDH@LP (OLL), by integrating ORI, Mn2+-containing LDH, and a folate-modified liposomal shell into one hybrid system. ORI serves as an ER stress inducer and ICD trigger, while Mn2+ promotes Fenton-like ROS generation and enhances cGAS-STING signaling. Compared with recently reported nanoplatforms that mainly exploit calcium overload or oxidative stress, such as Mn-based metal-organic frameworks (MOFs) and CaCO3 nanoparticles [[80], [81], [82], [83]]. OLL integrates multiple therapeutic modules within a single LDH-based platform. The Mn/Al LDH core enables pH-responsive and sustained co-release of ORI and Mn2+, allowing ORI-induced ER stress-associated calcium dysregulation to cooperate with Mn2+-mediated ROS generation and innate immune activation. As supported by our results, this design establishes a mutually reinforcing cascade involving calcium dysregulation, oxidative stress, ICD induction, and cGAS-STING-mediated immunomodulation, which may be difficult to achieve with simple calcium donors or single-function STING-activating nanocarriers. Moreover, the folate-modified liposomal shell may improve tumor accumulation and reduce nonspecific exposure, consistent with the favorable in vivo biosafety profile observed in this study [84]. Beyond direct tumor cell killing, OLL also effectively remodeled the immunosuppressive TME. The activation of ICD and cGAS-STING-related immune signaling was reflected by CRT exposure, HMGB1 release, increased type I interferon-related signaling, TAM repolarization toward an M1-like phenotype, and enhanced CD4+ and CD8+ T-cell infiltration. Flow cytometric analysis further showed an increased proportion of CD8+ T cells within the CD3+ population and elevated CD4+ and CD8+ T-cell numbers in the spleen, suggesting that OLL induced both local and systemic antitumor immune activation. These findings are consistent with previous reports showing that Mn2+ can enhance cGAS-STING signaling [72,85]. and further support the potential of OLL for treating immunologically “cold” tumors such as triple-negative breast cancer. From a translational perspective, OLL benefits from established liposomal nanomedicine strategies [86,87]. folate-mediated tumor targeting [83], and LDH-assisted ORI delivery [88]. Nevertheless, scalable manufacturing, long-term Mn2+/Al3+ safety, biodistribution, liposome-related immunogenicity, and large-animal validation remain key challenges [[89], [90], [91], [92], [93]]. Further pharmacokinetic, biodistribution, and long-term toxicity studies are therefore required before clinical translation. Despite these promising results, several limitations should be acknowledged. For example, tumor rechallenge experiments or assessments of tumor metastasis was not conducted in this study. Future studies should address these gaps by incorporating rechallenge models, metastasis evaluation, and more comprehensive immune cell profiling. Conclusion In this study, we engineered a multifunctional ORI-LDH@LP (OLL) nanoplatform that integrates the induction of endoplasmic reticulum stress with the activation of immunogenic cell death for enhanced breast cancer therapy. This OLL nanoplatform induces endoplasmic reticulum stress, activates the PERK–eIF2α–ATF4–CHOP axis, and strengthens the coupling between the endoplasmic reticulum and mitochondria via IP3R–GRP75–VDAC complex. These signaling cascades trigger mitochondrial calcium overload and excessive ROS production, thus forming a self-reinforcing vicious cycle among endoplasmic reticulum stress, calcium overload, and oxidative stress. This cycle ultimately leads to mitochondrial dysfunction and irreversible apoptosis. Importantly, the release of Mn2+ from OLL nanoplatform exerts a dual therapeutic effect. It induces immunogenic cell death through the generation of hydroxyl radicals via Fenton-like reaction; at the same time, Mn2+ directly activates the cGAS-STING signaling pathway. This activation further promotes the polarization of macrophages from the immunosuppressive M2 phenotype to the tumoricidal M1 phenotype and enhances the infiltration of cytotoxic T cells. Together, these immune responses successfully reshape the tumor immunosuppressive microenvironment. In the 4T1 mice model, OLL achieved strong tumor suppression without causing systemic toxicity. Overall, this work establishes a novel nanomaterial-driven paradigm for tumor microenvironment modulation and antitumor intervention. The OLL nanoplatform exhibits significant potential for overcoming tumor drug resistance and holds substantial promise for future clinical translation. Funding This study was supported by Yantai Science and Technology Bureau (Grant No. 2024JCYJ063), Science and Technology Support Plan for Youth Innovation of Colleges and Universities of Shandong Province of China (Grant No.2022KJ344), National Natural Science Foundation of China (Grant No.82001961, 82473967, 82273969, 22377104), Innovative Drug Research and Development National Science and Technology Major Project (2025ZD1800504), Taishan Scholar Project (tsqn202211112). CRediT authorship contribution statement Yucui Ding: Investigation, Validation, Visualization, Writing – original draft. Xinyu Liu: Investigation, Resources, Validation. Jianlong Fu: Resources, Validation. Jianyue Xue: Formal analysis, Resources. Xueni Fan: Resources. Yundong Wang: Resources. Xinrui Li: Resources. Sirui Liu: Resources. Yunchao Yang: Resources. Xiaopeng Xu: Resources. Gangqiang Yang: Resources. Hongbo Wang: Funding acquisition, Resources. Peng Zhang: Conceptualization, Funding acquisition, Project administration, Supervision, Validation, Writing – review & editing. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Footnotes Supplementary data to this article can be found online at https://doi.org/10.1016/j.mtbio.2026.103339. Contributor Information Hongbo Wang, Email: hongbowang@ytu.edu.cn. Peng Zhang, Email: peng.zhang@ytu.edu.cn. Supplementary data The following is the Supplementary data to this article: Multimedia component 1 Data availability Data will be made available on request. References Associated Data Supplementary Materials Multimedia component 1 Data Availability Statement Data will be made available on request.